Workflow
东方雨虹(002271):2024年年报点评:分红超预期化解风险,报表展现执行力

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 24.21 CNY, reflecting a potential upside based on current market conditions [1][12]. Core Insights - The company's annual report exceeded expectations with a cash dividend of 4.42 billion CNY, combined with a mid-year dividend of 1.46 billion CNY, totaling 5.88 billion CNY, which corresponds to an 18% dividend yield. This high dividend is expected to alleviate concerns regarding share pledges [12][13]. - The report highlights improvements in corporate governance through effective asset disposals and channel adjustments, indicating a strengthening execution capability [2][12]. - The company experienced a revenue decline of 14.5% year-on-year, with a reported revenue of 28.06 billion CNY for 2024, and a significant drop in net profit to 108 million CNY, down 95.2% [12][13]. Financial Summary - Revenue for 2023 was 32.82 billion CNY, with projections of 28.06 billion CNY for 2024, followed by a recovery to 30.77 billion CNY in 2025 [4][13]. - The net profit attributable to the parent company for 2023 was 2.27 billion CNY, with a drastic forecasted drop to 108 million CNY in 2024, before rebounding to 2.02 billion CNY in 2025 [4][13]. - The earnings per share (EPS) for 2023 was 0.93 CNY, expected to fall to 0.04 CNY in 2024, and recover to 0.83 CNY in 2025 [4][13]. Market Data - The company's stock price has fluctuated between 9.86 CNY and 17.85 CNY over the past 52 weeks, with a total market capitalization of 32.5 billion CNY [5][12]. - The company has a total equity of 24.93 billion CNY, with a book value per share of 10.23 CNY and a price-to-book ratio of 1.3 [6][12]. Future Outlook - The report anticipates continued focus on retail and new product categories, with expectations for revenue growth and profit recovery in 2025 [12][13]. - The company is expected to accelerate asset disposals in the first half of 2025, which may lead to further improvements in financial health [12][13].